AGM Statement

ABCAM PLC

("Abcam" or "the Company")

AGM Statement

Strong start to the new financial year

Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, is holding its Annual General Meeting this morning.

At the meeting Murray Hennessy, Abcam's Chairman, will make the following statement:

"Following a successful 2014/15 I am pleased to say that the current year has started well and we have confidence in our ability to achieve the financial and strategic targets we have set for ourselves over the coming year.

The positive momentum we reported in the last financial year has continued, which gives us confidence in the capital and operational investments we are making in the business. These will increase in the first half of the financial year; particularly given the higher run rate coming into the year, and the planned investment in Firefly BioWorks, which was acquired in January 2015. Our aim is to ensure that we are able to capitalise fully on the further opportunities available to us, whilst meeting our year-end financial targets.

In addition, as previously announced, we are investing to build a scalable and flexible IT platform that fits the needs of Abcam today and tomorrow. We are at the design and system selection phase of a 2 to 3 year project and will provide further information on our investment plans as they progress."

 For further information please contact:

Notes to Editors

About Abcam

Abcam plc is a provider of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services, multi-language support and next-day delivery in over 130 countries. The Company was founded in 1998, and now employs over 820 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com